Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA

Double, J.; Brown, Jeffrey R.

doi:10.1111/j.2042-7158.1976.tb04122.x

Cited by 40 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding may be related to the lack of thedaunosamine group which is postulated to be the moiety responsible for anthracyline myocardial damage [11].…”

Section: Introductionmentioning

confidence: 90%

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

Stein¹,

Borovik²,

Robinson³

1991

Oncology

View full text Add to dashboard Cite

Mitoxantrone (MIX), a member of the anthraquinone chemical class, was found to be a potential anticancer agent. It has a similar spectrum of activity as Adriamycin in experimental and human tumors. Thirty-five female patients with metastatic breast cancer, refractory to previous chemotherapy, were treated between 1986 and 1987 with MIX (14 mg/m² i.v. every 3 weeks); patients with diffuse bone metastases or heavily pretreated patients received 10–12 mg/m² MIX. All patients were evaluable for response and toxicity. Two patients achieved complete response and 4 partial response, giving an overall response rate of 17%. Median time of response was 5.5 months. The drug was well tolerated. Objective response was obtained mostly in patients with a performance status (Karnofsky scale) of more than 70%, and in those who received more than 12 mg/m² MIX per course. One patient developed cardiomyopathy, another an acute myocardial infarction, and 3 patients had pathological changes on echocardiography or multigated nuclear angiography. Hematological and gastrointestinal toxicity was tolerable. We found MIX to be a potentially effective second-line treatment with mild toxicity in patients with metastatic breast cancer.

show abstract

“…This finding may be related to the lack of thedaunosamine group which is postulated to be the moiety responsible for anthracyline myocardial damage [11].…”

Section: Introductionmentioning

confidence: 90%

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

Stein¹,

Borovik²,

Robinson³

1991

Oncology

View full text Add to dashboard Cite

show abstract

“…Novantrone | (mitoxantrone) is a new anthracenedione derivative synthesized in the hope of providing a compound with good clinical antitumor activity, but without cardiotoxicity. Similarly to doxorubicin, it binds to DNA and inhibits nucleic acid synthesis [9]. In phase II trials of Novantrone | in refractory NHL there were 24-43~ response rates [10,11].…”

Section: Introductionmentioning

confidence: 99%

Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma

Landys

1988

Invest New Drugs

View full text Add to dashboard Cite

Mitoxantrone (Novantrone) and prednimustine (Sterecyt) are both active as single agents in the treatment of unfavorable non-Hodgkin lymphoma (UNHL). The efficacy and toxicity of the combination of these agents (NOSTE) was evaluated in 28 patients with advanced histopathologically proven UNHL who were not eligible for aggressive conventional chemotherapy. The median age was 68, range 45-84. Sixteen patients were previously untreated. Eleven patients had received doxorubicin or epidoxorubicin containing regimens and 1 patient had received CVP as first line therapy. MUGA scan was used in monitoring cardiac function in patients with cardiac risk. Novantrone was administered at a dose of 8 mg/m2 IV on days 1 and 2 and Sterecyt as an absolute dose 100 mg/less than or equal to 1.6 m2-150 mg/greater than 1.6 m2 on days 1 through 5. The regimen was repeated every 4th week. The number of courses per patient ranged from 2 to 10. Objective response was obtained in 22 (78%) patients (20 CR and 2 PR). No response occurred in 6 patients (4 SD, 2 PD). Decreased left ventricular ejection fraction was recorded in 1 patient who suffered from asthma and ischemic heart disease. Hematological toxicity was tolerable. Gastrointestinal toxicity was rare. No hair loss was observed. After a median follow-up of 28 months the crude survival was 46%. Twelve of twenty complete responders are still in remission, the median duration of remission is 28.3 months, range 15-37. NOSTE in this pilot study showed a high response rate, good tolerance and mild toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…4), where the groups R, and R2 are 4 sugars -the chromoses A, B, C, D, but the only substances which have any value as cancerostatic agents in humans are those based on l:8-dihydroxyanthraquinone, e.g., daunomycin and adriamycin. It is likely, also considering the findings of Double and Brown (1976) that one requires an electronrich, completely planar molecule to intercalate well with DNA. (An anthrone has a butterfly shape and is therefore not planar.)…”

Section: Antitumor Activity Of the Anthraquinonesmentioning

confidence: 99%

“…As a result, it is a far less efficacious drug than dithranol in the treatment of psoriasis. Double and Brown (1976) have carried out a series of particularly careful studies to determine the requirements of anthraquinone chromophores for maximum binding to DNA and they con clude that the addition of a basic group into a three-or four-ringed chromophore (anthraqui none or naphthacenequinone), improved the intercalating power of the substance.…”

Section: Antitumor Activity Of the Anthraquinonesmentioning

confidence: 99%

Structure-Activity Relationships of Anthraquinones in Some Pathological Conditions

Friedmann¹

1980

Pharmacology

View full text Add to dashboard Cite

Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA

Cited by 40 publications

References 13 publications

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma

Structure-Activity Relationships of Anthraquinones in Some Pathological Conditions

Contact Info

Product

Resources

About